ReviewInternational journal of molecular sciences2016
Targeted Delivery Systems for Molecular Therapy in Skeletal Disorders.
Review in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 47 citations in OpenAlex.
- Artificial Intelligence-Driven Precision Bisphosphonate Therapy in Osteoporosis: Mechanisms, Clinical Applications, Risks, and Future Directions.Orthopaedic surgery · 2026Review
- Decoding Epigenetic Switches: How Histone Acetylation/Deacetylation Regulates Mononuclear/Macrophage Fate in Bone Disorders.International journal of biological sciences · 2026Review
- Liposome-mediated gene delivery: A comprehensive review of biophysical parameters, lipid composition and targeting strategies.ADMET & DMPK · 2026Review
- Engineering small-molecule and protein drugs for targeting bone tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Advances in Bone-Targeting Drug Delivery: Emerging Strategies Using Adeno-Associated Virus.Human gene therapy · 2024Review
- Surface-Modified Silica Hydrogels for the Programmable Release of Bisphosphonate Anti-Osteoporosis Drugs: The Case of Etidronate.Materials (Basel, Switzerland) · 2023Article
- miRNA-27a is essential for bone remodeling by modulating p62-mediated osteoclast signaling.eLife · 2023Article
- Targeted inhibition of osteoclastogenesis reveals the pathogenesis and therapeutics of bone loss under sympathetic neurostress.International journal of oral science · 2022Article
- Antiosteoporosis Effects, Pharmacokinetics, and Drug Delivery Systems of Icaritin: Advances and Prospects.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone.ACS central science · 2022Article
- Harnessing the power of antibodies to fight bone metastasis.Science advances · 2021Article
- The role of microRNAs in bone development.Bone · 2021Review
- Article
- Bone-Targeting Systems to Systemically Deliver Therapeutics to Bone Fractures for Accelerated Healing.Current osteoporosis reports · 2020Review
- Adjuvant Drug-Assisted Bone Healing: Advances and Challenges in Drug Delivery Approaches.Pharmaceutics · 2020Review
- Increased NF-kB activity in osteoprogenitor-lineage cells impairs the balance of bone versus fat in the marrow of skeletally mature mice.Regenerative engineering and translational medicine · 2020Article
- MicroRNAs are Critical Regulators of Osteoclast Differentiation.Current molecular biology reports · 2019Article
- In vivo SELEX of bone targeting aptamer in prostate cancer bone metastasis model.International journal of nanomedicine · 2019Article
- Bisphosphonate conjugation for bone specific drug targeting.Bone reports · 2018Review
- Bioreducible Poly(Amino Ethers) Based mTOR siRNA Delivery for Lung Cancer.Pharmaceutical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Abnormalities in the integral components of bone, including bone matrix, bone mineral and bone cells, give rise to complex disturbances of skeletal development, growth and homeostasis. Non-specific drug delivery using high-dose systemic administration may decrease therapeutic efficacy of drugs and increase the risk of toxic effects in non-skeletal tissues, which remain clinical challenges in the treatment of skeletal disorders. Thus, targeted delivery systems are urgently needed to achieve higher drug delivery efficiency, improve therapeutic efficacy in the targeted cells/tissues, and minimize toxicities in non-targeted cells/tissues. In this review, we summarize recent progress in the application of different targeting moieties and nanoparticles for targeted drug delivery in skeletal disorders, and also discuss the advantages, challenges and perspectives in their clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.